Citations

Clear

2429 citation(s) found for "Shah, SS".

Impact of a drug utilization review program on high‐risk use of prescription controlled substances
Daubresse, Matthew, Gleason, Patrick P., Shah, Nilay D. , Ritter, Stephen T., Peng, Yi , Alexander, G. Caleb

Mayo Clinic

Pharmacoepidemiology and Drug Safety | July 24, 2013 | Volume: 23 | Issue: 4 | Pages: 419-427

10.1002/pds.3487 | PMID 23881609 Get It

ABSTRACTBackgroundPrescription drug abuse has prompted considerable concern. We evaluated a retrospective drug utilization review program to reduce controlled substance use among individuals with high‐risk utilization.MethodsWe analyzed pharmacy claims from a large pharmaceutical benefits manager. For each eligible member, we calculated a controlled substance score based on the number and type of claims, prescribers and pharmacies, and utilization patterns over three months. Two state health plans sent controlled substance letters to prescribers of members meeting or exceeding a plan‐ and pre‐specified controlled substance score. Two different state health plans did not send such letters. We used a difference‐in‐difference design and generalized estimating equations to quantify the impact of the program on the mean difference in reduction of the controlled substance score over six months.ResultsEligible members in the intervention and comparison states had similar baseline mean controlled substance scores (19.0 vs. 18.6, p = 0.36). Adjusting for individuals' age, sex and pharmacy risk group score, reductions in the mean controlled substance score were greater in the intervention than comparison cohort (5.67 vs. 4.31, p = 0.01), corresponding with a 34.0% reduction in the intervention cohort compared to a 25.5% reduction in the comparison cohort. Changes were driven primarily by reductions in the number of controlled substance claims filled (30.5% vs. 23.1%, p = 0.01), as well as by a non‐statistically significant trend towards reductions in the number of prescribers and pharmacies used (26.9% vs. 20.1%, p = 0.07).ConclusionsRetrospective drug utilization review programs may reduce controlled substance scores and claims among individuals with patterns suggesting high‐risk utilization. Copyright © 2013 John Wiley & Sons, Ltd.
Emergency Physicians Accurately Interpret Video Capsule Endoscopy Findings in Suspected Upper Gastrointestinal Hemorrhage: A Video Survey
Meltzer, Andrew C. , Pinchbeck, Carrie, Burnett, Sarah, Buhumaid, Rasha , Shah, Payal , Fleischer, David E., Gralnek, Ian M. , Ding, Ru , Meltzer, Andrew C

Mayo Clinic

Academic Emergency Medicine | July 16, 2013 | Volume: 20 | Issue: 7 | Pages: 711-715

10.1111/acem.12165 | PMID 23859585 Get It

Cardiac magnetic resonance, transthoracic and transoesophageal echocardiography: a comparison of in vivo assessment of ventricular function in rats
Richardson, JD, Bertaso, AG, Psaltis, Peter J. , Koschade, B., Wong, DT, Nelson, Adam J. , Paton, Sharon , Williams, K., Azarisman, Shah M., Worthley, MI, Teo, KS, Gronthos, Stan , Zannettino, ACW, Worthley, SG, Frost, Lars , Carbone, Arnaldo , Zannettino, ACW, Worthley, Stephen G.

Mayo Clinic

Laboratory Animals | July 8, 2013 | Volume: 47 | Issue: 4 | Pages: 291-300

10.1177/0023677213494373 | PMID 23836849 Get It

In vivo assessment of ventricular function in rodents has largely been restricted to transthoracic echocardiography (TTE). However 1.5 T cardiac magnetic resonance (CMR) and transoesophageal echocardiography (TOE) have emerged as possible alternatives. Yet, to date, no study has systematically assessed these three imaging modalities in determining ejection fraction (EF) in rats. Twenty rats underwent imaging four weeks after surgically-induced myocardial infarction. CMR was performed on a 1.5 T scanner, TTE was conducted using a 9.2 MHz transducer and TOE was performed with a 10 MHz intracardiac echo catheter. Correlation between the three techniques for EF determination and analysis reproducibility was assessed. Moderate-strong correlation was observed between the three modalities; the greatest between CMR and TOE (intraclass correlation coefficient (ICC) = 0.89), followed by TOE and TTE (ICC = 0.70) and CMR and TTE (ICC = 0.63). Intra- and inter-observer variations were excellent with CMR (ICC = 0.99 and 0.98 respectively), very good with TTE (0.90 and 0.89) and TOE (0.87 and 0.84). Each modality is a viable option for evaluating ventricular function in rats, however the high image quality and excellent reproducibility of CMR offers distinct advantages even at 1.5 T with conventional coils and software.
Differences in Healthcare Utilization and Associated Costs Between Patients Prescribed vs. Nonprescribed Opioids During an Inpatient or Emergency Department Visit
Xie, Lin , Joshi, Ashish V. , Schaaf, David, Mardekian, Jack , Shah, Nilay D., Başer, Onur , Harnett, James

Mayo Clinic

Pain Practice | July 1, 2013 | Volume: 14 | Issue: 5 | Pages: 446-456

10.1111/papr.12098 | PMID 23809064 Get It

AbstractObjectivesCompare healthcare resource utilization (HCRU) and costs between patients prescribed opioids (RxOP) and those who were not (NoRxOP) during an emergency department (ED) or inpatient visit.MethodsRetrospective cohort analysis was performed (January 2006 to September 2010). Continuously eligible RxOP patients in ED/inpatient settings (January 2007 to September 2009) were included if age was ≥ 12 years by initial prescription date (or random date between first ED/inpatient admission and September 30, 2009 [NoRxOP patients]).Healthcare resource utilization and costs for 12 months after initial prescription were compared. Univariate descriptive analyses were performed for baseline and outcome variables and compared using appropriate tests. Risk adjustment compared HCRU between RxOP and NoRxOP cohorts for the postindex period.ResultsOf 27,599 eligible patients, RxOP patients (n = 18,819) were younger, less likely to be male, more likely to reside in southern United States and to have Preferred Provider Organization health plans, and had lower comorbidity index scores, compared with NoRxOP patients (n = 8,780). RxOP patients were less likely to have nonpain‐related comorbidities and more frequently diagnosed with pain‐related comorbidities.Unmatched and propensity‐matched RxOP patients experienced higher HCRU and costs in all subcategories (total, inpatient, outpatient ED, physician, pharmacy, other outpatient settings). Opioid abuse frequency was low in patients with common diagnoses/procedures within 3 months before initial prescription (0.48%). Average time to abuse was < 1 year (201 days).ConclusionMost patients were prescribed opioids initially during ED/inpatient visits and incurred higher HCRU than those not prescribed opioids. Among those with diagnosed opioid abuse after initiating opioids, time to diagnosis was rapid (range: 14 to 260 days) for patients with common diseases and procedures.
Nurses' attitudes, abilities and educational preference related to using family pedigrees in clinical practice
Pestka, Elizabeth L., Shah, Lisa , Junglen, Laura M., Delgado, Adriana, Meiers, Sonja J.

Mayo Clinic

International Journal of Nursing Practice | May 30, 2013 | Volume: No volume available | Issue: No issue available | Pages: n/a-n/a

10.1111/ijn.12091 | PMID 24093741 Get It

Determinants of fluoroscopy time for invasive coronary angiography and percutaneous coronary intervention: Insights from the NCDR®
Fazel, Reza , Curtis, Jeptha P. , Wang, Yongfei , Tsai, Thomas T., Chen, Jersey , Shah, Nilay D. , Nallamothu, Brahmajee K. , Einstein, Andrew Jeffrey , Smith‐Bindman, Rebecca , Krumholz, Harlan M.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 22, 2013 | Volume: 82 | Issue: 7 | Pages: 1091-1105

10.1002/ccd.24996 | PMID 23703793 Get It

ABSTRACTObjectivesIdentifying the distributions and determinants of fluoroscopy time for invasive coronary angiography (ICA) and percutaneous coronary intervention (PCI).BackgroundICA and PCI are significant contributors to radiation exposure from medical imaging in the US. Fluoroscopy time is a potentially modifiable determinant of radiation exposure for these procedures, but has not been well characterized in contemporary practice.MethodsWe evaluated the distribution of fluoroscopy time in patients undergoing ICA and/or PCI in the CathPCI Registry®, stratifying patients by numerous clinical scenarios. Hierarchical models were used to determine patient, procedure, operator and hospital‐level factors associated with fluoroscopy time for these procedures.ResultsOur study included a total of 3,295,348 ICA and PCI procedures performed by 9,600 operators from January 2005 through June 2009. There was wide variation in fluoroscopy times for these procedures with median [IQR] fluoroscopy times of 2.6 [1.7–4.5] minutes for ICA, 6.7 [4.2–10.8] minutes for ICA in patients with prior coronary artery bypass grafting (CABG), 10.1 [6.0–17.4] minutes for PCI, 10.7 [7.0–16.9] minutes for PCI with ICA, and 16.0 [10.6–24.0] minutes for PCI and ICA in patients with prior CABG. Prolonged fluoroscopy times (>30 minutes) were rare for ICA, but occurred in 6.7% of PCIs and 14.7% of PCIs in patients with prior CABG. After accounting for patient characteristics and procedure complexity, operator and hospital‐level factors explained nearly 20% of the variation in fluoroscopy time.ConclusionsFluoroscopy times vary widely during ICA and PCI with operator and hospital‐level factors contributing substantially to these differences. A better understanding of potentially modifiable sources of this variation will elucidate opportunities for enhancing the radiation safety of these procedures. © 2013 Wiley Periodicals, Inc.
Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival
Singal, Ashwani K. , Kamath, Patrick S. , Ziller, Nickie Francisco, DiCecco, Sara R. , Shoreibah, Mohamed , Kremers, Walter K. , Watt, Kymberly D. , Shah, Vijay H. , Charlton, Michael , Heimbach, Julie K. , Kremers, Walter K

Mayo Clinic

Transplant International | May 3, 2013 | Volume: 26 | Issue: 8 | Pages: 788-794

10.1111/tri.12123 | PMID 23751180 Get It

ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions
Verghese, Philip B. , Castellano, Joseph M. , Garai, Kanchan , Jiang, Hong , Shah, Aarti R., Bu, Guojun , Frieden, Carl , Wang, Yinong , Holtzman, David M. , Bu, Guojun

Mayo Clinic

Proceedings of the National Academy of Sciences | April 26, 2013 | Volume: 110 | Issue: 19 | Pages: No page available

10.1073/pnas.1220484110 | PMID 23620513 Get It

Significance It has been proposed that differential physical interactions of apolipoprotein E (apoE) isoforms with soluble amyloid-β (Aβ) in brain fluids influence the metabolism of Aβ, providing a major mechanism to account for how APOE influences Alzheimer’s disease risk. The current study challenges this proposal and clearly shows that lipoproteins containing apoE isoforms are unlikely to play a significant role in Aβ metabolism by binding directly to Aβ in physiological fluids such as cerebrospinal fluid or interstitial fluid. Our in vitro and in vivo results suggest that apoE isoforms influence Aβ metabolism by competing for the same clearance pathways within the brain.
Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial
Smallridge, Robert C., Copland, John A. , Brose, Marcia S. , Wadsworth, J. Trad , Houvras, Yariv , Menefee, Michael E., Bible, Keith C. , Shah, Manisha H. , Gramza, Ann W., Klopper, Joshua , Marlow, Laura A. , Roemeling, Reinhard von, Heckman, Michael G. , Marlow, Laura

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 15, 2013 | Volume: 98 | Issue: 6 | Pages: 2392-2400

10.1210/jc.2013-1106 | PMID 23589525 Get It

The Net Value of Health Care for Patients With Type 2 Diabetes, 1997 to 2005
Eggleston, Karen , Shah, Nilay D., Smith, Steven A., Wagie, Amy E., Grossman, Jerome H, Berndt, Ernst R. , Long, Kirsten Hall , Banerjee, Ritesh, Newhouse, Joseph P. , Williams, Arthur Robin , Banerjee, Ritesh

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 151 | Issue: 6 | Pages: 386-393

10.7326/0003-4819-151-6-200909150-00003 | PMID 19755364 Get It